ArticleBiological psychiatry2009
Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice.
Article in Biological psychiatry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 102 citations in OpenAlex.
- Sensorimotor circuit connectivity as a candidate biomarker for responsiveness to sertraline in obsessive-compulsive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Uncovering novel therapeutics for schizophrenia: a multitarget approach using the CANDO platform.bioRxiv : the preprint server for biology · 2026Article
- Hyperactivity of indirect pathway-projecting spiny projection neurons promotes compulsive behavior.Nature communications · 2024Article
- Mice lacking Ptprd exhibit deficits in goal-directed behavior and female-specific impairments in sensorimotor gating.PloS one · 2023Article
- Effects of repeated treatment with the 5-HTPsychopharmacology · 2022Article
- Analysis of independent cohorts of outbred CFW mice reveals novel loci for behavioral and physiological traits and identifies factors determining reproducibility.G3 (Bethesda, Md.) · 2022Article
- Distinct behavioral traits and associated brain regions in mouse models for obsessive-compulsive disorder.Behavioral and brain functions : BBF · 2021Article
- Disruption of prepulse inhibition is associated with compulsive behavior severity and nucleus accumbens dopamine receptor changes in Sapap3 knockout mice.Scientific reports · 2021Article
- Importance of dopaminergic neurotransmission for the RU 24969-induced locomotor activity of male and female rats during the preweanling period.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Serotonin 5-HTPsychopharmacology · 2021Article
- Bidirectional Behavioral Selection in Mice: A Novel Pre-clinical Approach to Examining Compulsivity.Frontiers in psychiatry · 2021Review
- Animal Models for OCD Research.Current topics in behavioral neurosciences · 2021Review
- Pharmacotherapeutic Strategies and New Targets in OCD.Current topics in behavioral neurosciences · 2021Review
- Effects of combined 5-HTPsychopharmacology · 2020Article
- Ketamine induces immediate and delayed alterations of OCD-like behavior.Psychopharmacology · 2020Article
- Btbd3 expression regulates compulsive-like and exploratory behaviors in mice.Translational psychiatry · 2019Article
- Article
- Dlgap1 knockout mice exhibit alterations of the postsynaptic density and selective reductions in sociability.Scientific reports · 2018Article
- Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.Neuroscience · 2017Review
- Of mice and marbles: Novel perspectives on burying behavior as a screening test for psychiatric illness.Cognitive, affective & behavioral neuroscience · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundObsessive-compulsive disorder (OCD) is characterized by intrusive thoughts, images, or impulses and/or repetitive stereotypical behavior. Obsessive-compulsive disorder patients exhibit reduced prepulse inhibition (PPI) and symptom exacerbation after challenge with 5-HT1B receptor agonists. Recently, gain-of-function alleles of the serotonin transporter (5-HTT) have been associated with OCD. We tested the hypothesis that reducing 5-HTT function chronically, either genetically or via serotonin reuptake inhibitor (SRI) treatment, attenuates PPI deficits and perseverative hyperlocomotion induced by 5-HT1B agonists in mice.
methodsMice received subchronic or chronic pretreatment with the SRI fluoxetine and acute treatment with RU24969 (5-HT1A/1B agonist) or 8-OH-DPAT (5-HT1A agonist) and were assessed for PPI, locomotor activity, and spatial patterns of locomotion. The same measures were evaluated in 5-HTT wild-type (WT), heterozygous (HT), and knockout (KO) mice after RU24969 treatment. The effects of WAY100635 (5-HTA antagonist) or GR127935 (5-HT1B/D antagonist) pretreatment on RU24969-induced effects were evaluated. Finally, 5-HT1B binding and functional coupling were assessed in 5-HTT-WT, -HT, and -KO mice, and normal fluoxetine-treated mice.
resultsChronic, but not subchronic, fluoxetine treatment prevented RU24969-induced PPI deficits and perseverative hyperlocomotion. These RU24969-induced effects were mediated via 5-HT1B and not 5-HT1A receptors. 5-HTT-KO mice showed no effects of RU24969, and 5-HTT-HT mice exhibited intermediate phenotypes. 5-HT1B binding and functional coupling were reduced in the globus pallidus and substantia nigra of 5-HTT-KO mice.
conclusionsOur results demonstrate that chronic, but not subchronic, fluoxetine treatment and 5-HTT knockout robustly attenuate 5-HT1B agonist-induced PPI deficits and perseverative hyperlocomotion. These results may have implications for the etiology and treatment of OCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.